We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva: FDA Should Allow Flexible Standards in New Biosimilars Pathway
Teva: FDA Should Allow Flexible Standards in New Biosimilars Pathway
November 5, 2010
Teva is calling on the FDA to adopt flexible standards once it approves a biosimilar for its initial indication, saying that no additional testing should be required to have a product deemed interchangeable or to approve additional indications.